ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 148 filers reported holding ACCELERON PHARMA INC in Q4 2016. The put-call ratio across all filers is 3.41 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $22,692,000 | -3.9% | 889,177 | +36.3% | 0.02% | -4.2% |
| Q3 2016 | $23,603,000 | +7.0% | 652,195 | +0.5% | 0.02% | +9.1% |
| Q2 2016 | $22,050,000 | +23.7% | 648,917 | -3.9% | 0.02% | +15.8% |
| Q1 2016 | $17,819,000 | -28.2% | 675,209 | +32.7% | 0.02% | -26.9% |
| Q4 2015 | $24,810,000 | +95.6% | 508,816 | -0.1% | 0.03% | +85.7% |
| Q3 2015 | $12,687,000 | -19.2% | 509,489 | +2.6% | 0.01% | -12.5% |
| Q2 2015 | $15,710,000 | -11.8% | 496,517 | +6.1% | 0.02% | -11.1% |
| Q1 2015 | $17,811,000 | +3.5% | 467,976 | +6.0% | 0.02% | +5.9% |
| Q4 2014 | $17,205,000 | +167.7% | 441,625 | +107.8% | 0.02% | +183.3% |
| Q3 2014 | $6,427,000 | -20.1% | 212,537 | -10.2% | 0.01% | -25.0% |
| Q2 2014 | $8,042,000 | +1.8% | 236,743 | +3.4% | 0.01% | 0.0% |
| Q1 2014 | $7,898,000 | -4.6% | 228,919 | +9.5% | 0.01% | 0.0% |
| Q4 2013 | $8,282,000 | – | 209,146 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |